PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle mass alongside GLP-1 therapies. This emerging category is gaining industry attention due to its potential to enhance body composition and patient results, supported by strategic acquisitions like Eli Lilly's purchase of Versanis Bio. The report suggests muscle-preservation therapies will complement rather than replace GLP-1 drugs, creating new opportunities in pharmaceutical partnerships, licensing, and intellectual property. This marks a shift in obesity treatment focus from just weight loss to improving the quality of weight loss over time.
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
Eli Lilly's shares rose nearly 6% following the European Medicines Agency's CHMP recommendation to approve Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all therapy lines. This approval would allow use regardless ...
GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are driving high demand among employees, but their high costs are causing many large employers to reduce or reconsider coverage. Although oral pills are as expensive as injectables and less effe...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for treating adults with chronic lymphocytic leukemia (CLL) across all lin...
ProQR Therapeutics has priced a $50 million underwritten registered direct offering of 27.6 million shares at $1.81 each, alongside a concurrent private placement of 5.1 million shares to Eli Lilly for $9.2 million. The funds will support ProQR's RNA...
